Stoke Therapeutics, Inc. (STOK) SEC Filings & Earnings Calls
EquiReason read 17 Stoke Therapeutics, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-25 — Director Edward M. Kaye resigned; Alexander (Bo) Cumbo appointed as Class III director. Standard compensation: $45k cash retainer and initial stock option for 39,674 shares (~$724k.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
25 Sep 20268-K · 5.02Director Edward M. Kaye resigned; Alexander (Bo) Cumbo appointed as Class III director. Standard compensation: $45k cash retainer and initial stock option for 39,674 shares (~$724k grant date fair value).open
Figures in the filing · each found in the filing text
| annual cash retainer | $45000.00 | |
| initial stock option shares | 39,674 | |
| target grant date fair value | $724000.00 |
3 Aug 20268-K · 2.02Cash, cash equivalents and marketable securities $420M; Cash, cash equivalents and marketable securities (June 30, 2026) $354M; ATM sale proceeds $66Mearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · 2026-08-03 | $420M | |
| Cash, cash equivalents and marketable securities (June 30, 2026) · Q2-2026 | $354M | |
| ATM sale proceeds · 2026-08-03 | $66M | |
| Phase 3 EMPEROR enrollment · 2026-06 | $162.00 |
Risks flagged
Clinical trial risk: Phase 3 EMPEROR data readout not expected until Q3 2027; no revenue generating products yet.
“Phase 3 readout anticipated in the third quarter of 2027; no approved products.”
3 Aug 20268-K · 8.01Stoke Therapeutics filed a prospectus supplement to offer and sell up to $200M of common stock in an at-the-market offering under existing Sales Agreement with Cantor Fitzgerald. Potential dilution for existing shareholders.open
Figures in the filing · each found in the filing text
| ATM offering amount · 2026-08-03 | $200M |
Risks flagged
ATM offering could dilute existing shareholders if shares are sold at market prices.
“Prospectus supplement for up to $200M of common stock at market prices.”
3 Aug 202610-QStoke Therapeutics reported a net loss of $61.6M in Q2 2026, widening from $23.5M in Q2 2025, as R&D and SG&A expenses increased significantly while revenue declined.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $9M | -33% y/y |
| Net (loss) income · Q2-2026 | $-62M | |
| Research and development expense · Q2-2026 | $50M | +92% y/y |
| Cash and cash equivalents · 2026-06-30 | $110M | |
| Accumulated deficit · 2026-06-30 | $-609M |
Risks flagged
Clinical trial failure risk
“The Company is a late-stage clinical company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines.” · word for word
Liquidity risk
“The Company expects that its operating losses and negative cash flows will continue for the foreseeable future.” · word for word
Dependence on collaborations
“Revenue is entirely from collaboration agreements (Biogen, Acadia); no product revenue.”
30 Jun 20268-K · 7.01, 8.01Stoke Therapeutics completed enrollment of 162 patients in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome; data readout expected Q3 2027; rolling NDA submission to FDA planned Q1 2027.open
Figures in the filing · each found in the filing text
| patients enrolled in Phase 3 EMPEROR study · Q2-2026 | 162 | |
| patients through 28 weeks of treatment · Q2-2026 | 50 |
Risks flagged
Phase 3 data readout not expected until Q3 2027; regulatory and commercial success uncertain.
“A Phase 3 data readout is anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the second half of 2027.” · word for word
7 May 202610-QRevenue $6M (-96% y/y); Net loss $-50M; Research and development expense $40M (+21% y/y)open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $6M | -96% y/y |
| Net loss · Q1-2026 | $-50M | |
| Research and development expense · Q1-2026 | $40M | +21% y/y |
| Cash and cash equivalents · Q1-2026 | $156M | |
| Accumulated deficit · Q1-2026 | $-548M | |
| Operating cash flow · Q1-2026 | $-61M |
Risks flagged
Dependence on Biogen collaboration for revenue
“Revenue dropped from $158.6M in Q1 2025 to $6.2M in Q1 2026, primarily due to the Biogen upfront payment recognized in Q1 2025.”
Significant operating losses
“Net loss $50.0M for Q1 2026.”
Clinical and regulatory risk for zorevunersen
“Zorevunersen is in Phase 3 development; no guarantee of success.”
7 May 20268-K · 2.02New 4-year OLE data for zorevunersen in Dravet syndrome show statistically significant improvements in cognition and behavior, durable seizure reductions, and favorable safety profile. Phase 3 EMPEROR enrollment on track for June 2026 complopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q1-2026 | $411M | |
| Revenue · Q1-2026 | $6M | -96% y/y |
Risks flagged
Revenue decline due to prior year milestone recognition; ongoing reliance on pipeline success
“Revenue $6.2M vs $158.6M YoY (prior year included milestone payments)”
Clinical trial execution risk for Phase 3 EMPEROR and earlier-stage pipeline
“Phase 3 enrollment completion expected June 2026; data readout mid-2027”
22 Apr 2026DEF 14AProxy statement discloses new permanent CEO appointed in October 2025 with significant equity incentives; former CEO transitioned to advisor roleopen
Figures in the filing · each found in the filing text
| Shares Outstanding · 2026-04-07 | 62,271,082 | |
| Net Loss · FY2025 | $-7M | |
| Total Shareholder Return (3-year) · 2025-12-31 | $343.88 |
Risks flagged
Pre-revenue biotech with accumulated deficit
“Net Income ($ Thousands) ... ( 6,885 )”
Key person dependence on new CEO
“Ian F. Smith has served as our Chief Executive Officer since October 2025” · word for word
7 Apr 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
No new risks identified; standard board appointment disclosure.
“No mention of financial metrics, guidance changes, or operational risks.”
27 Mar 20268-K · 4.01Changed its independent registered accounting firm; filed financial statements and exhibits with this reportopen
Risks flagged
Auditor change may signal governance risk, but no disagreements or reportable events mitigate concern.
“No disagreements or reportable events; KPMG reports unqualified.”
16 Mar 202610-KRisks named: Clinical trial failure risk, Funding risk, Regulatory approval delay riskopen
Risks flagged
Clinical trial failure risk
“Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials, including in our Dravet syndrome program or our ADOA program.” · word for word
Funding risk
“We have a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future.” · word for word
Regulatory approval delay risk
“Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate.” · word for word
3 Mar 20268-K · 5.02CEO bonus $697,125.00open
Figures in the filing · each found in the filing text
| CEO bonus · FY2025 | $697125.00 |
26 Jan 20268-K · 1.01, 2.03Stoke Therapeutics entered a new lease for 98,500 sq ft corporate HQ and lab space with aggregate base rent of ~$85.5M through 2038, plus two 5-year extension options. A $3M letter of credit security deposit is required.open
Figures in the filing · each found in the filing text
| Aggregate base rent · 2026-2038 | $86M | |
| Lease square footage · 2026 | $98500.00 |
Risks flagged
New lease creates long-term obligation; $85.5M aggregate rent.
“aggregate estimated base rent payments due over the term of the Lease Agreement is approximately $85.5 million” · word for word
12 Jan 20268-K · 2.02, 7.01, 8.01Cash, cash equivalents and marketable securities $392Mearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · FY2025 | $392M |
Risks flagged
Preliminary financial data subject to adjustment; clinical trial timelines subject to change.
“The Company’s audited financial statements for the fiscal year ended December 31, 2025, are not yet available.” · word for word
5 Dec 20258-K · 7.01, 8.01Doses administered 800open
Figures in the filing · each found in the filing text
| Doses administered · Q4-2025 | 800 |
Risks flagged
Safety profile includes CSF protein elevations (42% in Phase 1/2a, 86% in OLE) and three deaths (unrelated per company).
“CSF protein elevations >50 mg/dL in 42% of Phase 1/2a patients and 86% of OLE patients; three deaths reported (SUDEP and malnutrition), all assessed unrelated.”
4 Nov 20258-K · 2.02Revenue $11M (+116% y/y); Net Loss $-38M; Cash, Cash Equivalents, and Marketable Securities $329Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $11M | +116% y/y |
| Net Loss · Q3-2025 | $-38M | |
| Cash, Cash Equivalents, and Marketable Securities · Q3-2025 | $329M | |
| Research and Development Expenses · Q3-2025 | $38M | +70% y/y |
Risks flagged
Clinical trial risk: Phase 3 EMPEROR study enrollment may face delays or fail to meet endpoints.
“Global Phase 3 EMPEROR study patient recruitment ongoing... Study on track to complete enrollment in second half of 2026” · word for word
4 Nov 202510-QStoke Therapeutics reported a significant revenue increase due to the Biogen collaboration upfront payment, turning profitable on a year-to-date basis.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $183M | +1213% y/y |
| Net income (loss) · Q3-2025 | $51M | |
| Cash and cash equivalents · Q3-2025 | $83M | |
| Marketable securities · Q3-2025 | $245M | |
| Research and development expense · Q3-2025 | $96M | +46% y/y |
| Accumulated deficit · Q3-2025 | $440M |
Risks flagged
Clinical trial risk
“The Company is a late-stage clinical-stage company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines.” · word for word
Dependence on collaboration
“Revenue is heavily dependent on the Biogen collaboration; without it, the company would still be pre-revenue.”
Operating loss history
“The Company expects that its operating losses and negative cash flows will continue for the foreseeable future.” · word for word
Stoke Therapeutics, Inc. — questions
- What did Stoke Therapeutics, Inc. file recently?
- 17 SEC filings in the last 12 months. Latest: 8-K on 2026-09-25 — Director Edward M. Kaye resigned; Alexander (Bo) Cumbo appointed as Class III director. Standard compensation: $45k cash retainer and initial stock option for 39,674 shares (~$724k grant date fair value).
Every figure on this page comes from Stoke Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.